Meta AnalysisID 6743
参松养心胶囊联合常规西药治疗脑心综合征：一项系统评价与Meta分析
CRD42023478550
Shensong Yangxin (SSYX) capsule is widely used in clinic and is an important drug in the guidelines for rational drug use of arrhythmia in China. Evaluating the effectiveness and safety of combining these two medications
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Formula: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 6743
- Evidence Id
- 15301
- Core Evidence Id
- 15301
- Source Meta Analysis Id
- 6727
- Herb2 Meta Analysis Id
- HBMA006727
- Crd Id
- CRD42023478550
- Title
- Shensong Yangxin Capsule and Conventional Medicine Combination for Cerebral-cardiac syndrome: A systematic review and meta-analysis
- Review Question
- Shensong Yangxin (SSYX) capsule is widely used in clinic and is an important drug in the guidelines for rational drug use of arrhythmia in China. Evaluating the effectiveness and safety of combining these two medications for treating cerebral-cardiac syndrome is essential.
- Study Type Included
- The studies which were included must be clinical randomized controlled studies (RCTs) with a total sample size of more than 60.Non-randomised clinical studies (NRS), observational studies, and case studies were excluded.
- Condition Being Studied
- Shensong Yangxin Capsule is widely used in clinic and is an important drug in the guidelines for rational drug use of arrhythmia in China (Zhang et al. 2014). The cerebral-cardiac syndrome is divided into two types according to the timing of heart and brain onset, One type is the heart injury occurs after the cranial lesion, and the other type is the heart injury and cranial lesion occur almost simultaneously (Hu Y and Zhang X.2019). In 1947, BYER E reported the world's first case of secondary ST-T changes in the ECG after acute stroke (BYER E et al. 1947). Until now，the incidence of cerebral-cardiac syndrome ranges from 62% to 90% (Huang SJ and Bai X. 2014), with an acute onset and high risk of multi-organ and multi-system failure and there is no effective treatment option. Shensong Yangxin (SSYX) capsule is widely used in the treatment of cardiovascular diseases. This study was based on the clinical randomized controlled trials of SSYX combined with conventional medical therapy for the treatment of cerebral-cardiac syndrome，and used evidence-based medicine methods to systematically evaluate the efficacy and safety of this drug.
- Participant
- The study will consider participants had been diagnosed as cerebral-cardiac syndrome, and no restrictions on their gender, severity and disease duration.
- Animal
- Human Disease Modelled
- Intervention
- The experimental group was used Shensong Yangxin Capsule, or combined with conventional western medicine to treat Cerebral-cardiac syndrome, all treatment plans should account for the dosage and the duration of drug use.
- Comparator Control
- The control measure should be defined as placebo or other conventional western medicine, with clear reporting of the method of medication, dosage and course of treatment.
- Main Outcome
- The Main outcome indicators should involve clinical response rate, incidence of adverse reactions, the changes of electrocardiogram (ECG), and the levels of norepinephrine (NE). Measures of effect Odds ratios (OR) were used for binary variables, while mean differences (MD) were employed for continuous variables, with corresponding 95% confidence intervals (CI) for each effect size during the evaluation process.
- Outcome Measure
- Additional Outcome
- The Main outcome indicators should involve epinephrine (E), dopamine (DA), Malondialdehyde (MDA) and Superoxide Dismutase (SOD). Measures of effect Odds ratios (OR) were used for binary variables, while mean differences (MD) were employed for continuous variables, with corresponding 95% confidence intervals (CI) for each effect size during the evaluation process.
- Study Method
- Meta-analysis, Systematic review
- Keyword
- MeSH headings have not been applied to this record
- Contact
- Qiang Fu [email protected]
- Organisational Affiliation
- Chongqing Hospital of Traditional Chinese Medicine
- Funding Source
- This study was supported by theNational Natural Science Foundation of China (81973824), the National Natural Science Foundation of China (82004308), the Jiangsu Province Traditional Chinese Medicine Leading Talent Project (SLJ0204), the Jiangsu Administration of Traditional Chinese Medicine (ZD201703), the National Administration of Traditional Chinese Medicine: 2019 Project of building evidence-based practice capacity for TCM (2019XZZX-XXG004), the Priority Academic Program Development of Jiangsu Higher Education Institutions (Integration of Chinese and Western Medicine), and the fifth phase of “Project 333” scientific research project of Jiangsu Province.
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2023-11-01
- Registration Date
- 2023-11-12
- Anticipated Start Date
- 2023-10-01
- Anticipated Completion Date
- 2023-12-31
- Title Cn
- 参松养心胶囊联合常规西药治疗脑心综合征：一项系统评价与Meta分析
- Title En
- Shensong Yangxin Capsule and Conventional Medicine Combination for Cerebral-cardiac syndrome: A systematic review and meta-analysis
- Bilingual Status
- complete